Published in Radiat Oncol on May 30, 2010
The histopathological spectrum of human meningiomas. Int J Clin Exp Pathol (2012) 1.08
Current concepts in clinical radiation oncology. Radiat Environ Biophys (2013) 0.97
EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas. Oncol Lett (2014) 0.85
EGFR soluble isoforms and their transcripts are expressed in meningiomas. PLoS One (2012) 0.80
Molecular Targets and Treatment of Meningioma. J Neurol Neurosurg (2014) 0.80
Expression of CD163 prevents apoptosis through the production of granulocyte colony-stimulating factor in meningioma. Neuro Oncol (2013) 0.80
Expression and clinical value of EGFR in human meningiomas. PeerJ (2017) 0.75
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol (1995) 9.03
Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res (2002) 4.97
Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg (1985) 3.73
Expression of epidermal growth factor receptors in human brain tumors. Cancer Res (1984) 2.83
Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg (1994) 2.00
Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol (1986) 1.83
Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer (1996) 1.66
Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol (2004) 1.46
EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol (1998) 1.39
Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs (2007) 1.24
Radiation therapy in the treatment of partially resected meningiomas. Neurosurgery (1987) 1.18
The EGF receptor system as a target for antitumor therapy. Cancer Invest (1991) 1.11
Effect of epidermal growth factor on membrane motility and cell locomotion in cultures of human clonal glioma cells. J Neurosci Res (1982) 1.09
The meningioma controversy: postoperative radiation therapy. Int J Radiat Oncol Biol Phys (1988) 1.04
High throughput screening of meningioma biomarkers using a tissue microarray. J Neurooncol (2005) 0.98
Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int J Radiat Oncol Biol Phys (1996) 0.97
EGF-R expression in ductal breast cancer: proliferation and prognostic implications. Anticancer Res (1997) 0.95
Expression and activation of epidermal growth factor receptors in meningiomas. J Neurosurg (1997) 0.93
Association between absence of epidermal growth factor receptor immunoreactivity and poor prognosis in patients with atypical meningioma. J Neurosurg (2007) 0.90
Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis. J Neurol (1995) 0.88
EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets (2007) 0.87
Characterization of the epidermal growth factor receptor in human meningioma. Cancer Res (1987) 0.86
The place of targeted therapy in the patient management of non-small cell lung cancer. Lung Cancer (2007) 0.86
The epidermal growth factor receptor is associated with phospholipase C-gamma 1 in meningiomas. Hum Pathol (1994) 0.84
Epidermal growth factor receptor expression in 72 meningiomas. Cancer (1990) 0.84
Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. Curr Pharm Des (2007) 0.84
Detection of epidermal growth factor and transforming growth factor alpha protein in meningiomas and other tumors of the central nervous system in human beings. Surg Gynecol Obstet (1993) 0.83
Epidermal growth factor receptor in human brain tumors. J Endocrinol Invest (1992) 0.82
Epidermal growth factor receptor in meningiomas is expressed predominantly on endothelial cells. Cancer (1988) 0.82
Erlotinib in non-small-cell lung cancer. Expert Opin Pharmacother (2007) 0.81
A comparative study of epidermal growth factor receptor (EGFR) and MDM2 gene amplification and protein immunoreactivity in human glioblastomas. Pol J Pathol (1998) 0.80
Acquired rearrangement of an amplified epidermal growth factor receptor (EGFR) gene in a human glioblastoma xenograft. J Neuropathol Exp Neurol (1999) 0.80
First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Clin Colorectal Cancer (2007) 0.80
Regulation of DNA synthesis and growth of cells derived from primary human meningiomas. Cancer Res (1986) 0.80
Influence of epidermal growth factor and gastrin on the cell proliferation of human meningiomas versus astrocytic tumors maintained as ex vivo tissue cultures. Neuropeptides (1997) 0.78
[Measurement of epidermal growth factor receptor concentration in the pre- and postoperative serum in patients with meningiomas]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao (2002) 0.77
Epidermal growth factor--receptors on cultured human meningioma cells. Acta Neurochir (Wien) (1986) 0.77
Epidermal growth factor receptor activity and clinical outcome in glioblastoma and meningioma. Br J Neurosurg (1993) 0.77
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell (2008) 5.75
Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell (2007) 5.40
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med (2015) 5.03
Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res (2002) 4.97
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology (2008) 3.28
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
Histological classification and molecular genetics of meningiomas. Lancet Neurol (2006) 3.19
Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO J (2005) 3.11
Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res (2007) 3.05
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol (2008) 3.02
Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys (2010) 2.94
Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res (2004) 2.90
Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol (2011) 2.82
Embedded together: the life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis (2007) 2.82
Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res (2004) 2.79
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
A randomized controlled trial of the impact of targeted and tailored interventions on colorectal cancer screening. Cancer (2007) 2.64
Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell (2012) 2.45
Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol (2006) 2.41
Bcl-XL inhibits membrane permeabilization by competing with Bax. PLoS Biol (2008) 2.36
Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials. J Natl Cancer Inst (2013) 2.35
Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol (2012) 2.35
Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res (2003) 2.30
Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol (2010) 2.30
Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res (2003) 2.24
Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res (2007) 2.15
The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 2.13
Interaction with a membrane surface triggers a reversible conformational change in Bax normally associated with induction of apoptosis. J Biol Chem (2003) 2.12
Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data. Int J Radiat Oncol Biol Phys (2012) 2.12
Reactive retinal astrocytic tumors (so-called vasoproliferative tumors): histopathologic, immunohistochemical, and genetic studies of four cases. Am J Ophthalmol (2012) 2.12
The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis. Int J Radiat Oncol Biol Phys (2012) 2.10
Adult medulloblastoma comprises three major molecular variants. J Clin Oncol (2011) 2.07
Pathological classification and molecular genetics of meningiomas. J Neurooncol (2010) 2.03
Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene (2002) 1.99
A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov (2013) 1.97
Bcl-2 changes conformation to inhibit Bax oligomerization. EMBO J (2006) 1.97
The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.96
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol (2007) 1.95
Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain (2007) 1.94
MicroRNA genes are frequently located near mouse cancer susceptibility loci. Proc Natl Acad Sci U S A (2007) 1.90
p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci U S A (2009) 1.89
Multifocal glioblastoma multiforme: prognostic factors and patterns of progression. Int J Radiat Oncol Biol Phys (2007) 1.87
Medullomyoblastoma: a radiographic and clinicopathologic analysis of six cases and review of the literature. Cancer (2004) 1.84
Spindle cell oncocytoma of the adenohypophysis: report of two recurrent cases. Am J Surg Pathol (2005) 1.84
Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol (2011) 1.83
Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res (2006) 1.80
Tailored navigation in colorectal cancer screening. Med Care (2008) 1.79
BH3-only proteins: Orchestrators of apoptosis. Biochim Biophys Acta (2010) 1.76
Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer (2011) 1.76
Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression. Clin Cancer Res (2008) 1.75
Differentiation and definition of vascular-targeted therapies. Clin Cancer Res (2005) 1.74
Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb Perspect Biol (2013) 1.73
Glioblastoma. Arch Pathol Lab Med (2007) 1.71
During apoptosis bcl-2 changes membrane topology at both the endoplasmic reticulum and mitochondria. Mol Cell (2004) 1.71
The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.70
Improving prognosis of glioblastoma in the 21st century: who has benefited most? Cancer (2011) 1.70
Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol (2008) 1.69
Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res (2007) 1.69
Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathol (2013) 1.68
Impact of a physician-oriented intervention on follow-up in colorectal cancer screening. Prev Med (2004) 1.68
Auto-activation of the apoptosis protein Bax increases mitochondrial membrane permeability and is inhibited by Bcl-2. J Biol Chem (2006) 1.65
Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res (2005) 1.63
Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov (2012) 1.63
G protein-coupled receptor kinase 2 expression and activity are associated with blood pressure in black Americans. Hypertension (2009) 1.62
Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies. Cancer Res (2005) 1.62
Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas. Brain Pathol (2008) 1.59
Impact of a standardized protocol and antibiotic-impregnated catheters on ventriculostomy infection rates in cerebrovascular patients. Neurosurgery (2010) 1.56
RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys (2012) 1.56
Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer (2003) 1.56
The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle (2011) 1.55
VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys (2007) 1.55
Assessing the value of an optional radiation oncology clinical rotation during the core clerkships in medical school. Int J Radiat Oncol Biol Phys (2012) 1.54
Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene (2005) 1.53
Prognostic factors and outcomes after definitive treatment of female urethral cancer: a population-based analysis. Urology (2012) 1.53
Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. Cancer Res (2009) 1.52
BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Mol Cell (2013) 1.48
Problems with co-funding in Canada. Science (2005) 1.48
Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res (2008) 1.47
Technique of outpatient placement of intraprostatic fiducial markers before external beam radiotherapy. Urology (2009) 1.45
Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res (2007) 1.44
Effect of percentage of positive prostate biopsy cores on biochemical outcome in low-risk PCa treated with brachytherapy or 3D-CRT. Urology (2009) 1.43
Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med (2007) 1.43
A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin Cancer Res (2006) 1.42
Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol (2008) 1.41
Reasons patients with a positive fecal occult blood test result do not undergo complete diagnostic evaluation. Ann Fam Med (2009) 1.41
DNA sequence of the translocation breakpoints in undifferentiated embryonal sarcoma arising in mesenchymal hamartoma of the liver harboring the t(11;19)(q11;q13.4) translocation. Genes Chromosomes Cancer (2007) 1.40
Membrane-bound fatty acid desaturases are inserted co-translationally into the ER and contain different ER retrieval motifs at their carboxy termini. Plant J (2004) 1.40
Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol (2004) 1.39
Atypical teratoid/rhabdoid tumor with ganglioglioma-like differentiation: case report and review of the literature. Hum Pathol (2013) 1.39
Factorial validity and invariance of a survey measuring psychosocial correlates of colorectal cancer screening among African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev (2005) 1.38
Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res (2013) 1.35
Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol (2015) 1.35